Publicaciones en las que colabora con Alvaro Ruibal Morell (12)

2023

  1. Role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT): From biology to theragnosis

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 3, pp. 156-162

2020

  1. Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

    World Journal of Gastroenterology, Vol. 26, Núm. 13, pp. 1513-1524

2016

  1. HIN-1: a New Epigenetic Biomarker Crucial for Therapy Selection in Glioblastoma Multiforme

    Molecular Neurobiology, Vol. 53, Núm. 3, pp. 1802-1807

2014

  1. CA15.3 serum concentrations in older women with infiltrating ductal carcinomas of the breast

    International Journal of Molecular Sciences, Vol. 15, Núm. 11, pp. 19870-19876

  2. Pancreatic ductal adenocarcinoma: Implications of epigenetic role related the src pathway

    Journal of Cancer Science and Therapy, Vol. 6, Núm. 2, pp. 045-051

2013

  1. A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer

    BMC Genomics, Vol. 14

2009

  1. Egfr expression correlates with maximum standardized uptake value of 18- fluorodeoxyglucose-pet in squamous cell lung Carcinoma

    Current Radiopharmaceuticals, Vol. 2, Núm. 3, pp. 175-176

  2. El máximo valor de captación estandarizado en la 18F-FDG PET es independiente de la expresión inmunohistoquímica del factor de crecimiento endotelial derivado de las plaquetas en pacientes con carcinoma de pulmón no microcítico

    Medicina Clinica

  3. La expresión inmunohistoquímica intensa de ciclooxigenasa 2 se asocia inversamente con los valores máximos de SUV en la 18F-FDG-PET de pacientes afectados de carcinomas no microcíticos de pulmón. Relación con otros factores biológicos

    Revista española de medicina nuclear, Vol. 28, Núm. 1, pp. 11-14

  4. The immunohistochemical expression of cyclin B1 is associated with higher SUV in 18F-FDG-PET in non-sma ll cell lung cancer patients. Initial results

    Revista Espanola de Medicina Nuclear, Vol. 28, Núm. 2, pp. 63-65

  5. The immunohistochemical expression of cyclooxygenasa 2 is inversely associated with 18F-FDG-PET SUV values in non-small cell lung cancers. Initial results

    Revista Espanola de Medicina Nuclear, Vol. 28, Núm. 1, pp. 11-14

2006

  1. A case of orbital malt lymphoma with breast involvement detected by 18FDG-positron emission tomography

    British Journal of Haematology, Vol. 133, Núm. 3, pp. 220